RZLT

Rezolute is a late-stage rare disease company developing ersodetug, a human monoclonal antibody that modulates insulin signaling for the treatment of hypoglycemia caused by hyperinsulinism. The company's lead program, ersodetug, is currently in Phase 3 development with the sunRIZE trial for congenital hyperinsulinism and the upLIFT trial for tumor hyperinsulinism, both expected to generate topline data in 2025. Ersodetug has received Breakthrough Therapy Designation from the FDA for both congenital and tumor hyperinsulinism, along with Orphan Drug Designation and PRIME designation in Europe.

Pipeline

Catalyst Calendar